Literature DB >> 10663452

Site of nicotine absorption from a vapour inhaler--comparison with cigarette smoking.

E Lunell1, L Molander, K Ekberg, J Wahren.   

Abstract

OBJECTIVE: The aim of the study was to assess the site of nicotine absorption during and after use of a nicotine-vapour inhaler compared with that after cigarette smoking.
METHODS: Using a catheterisation technique, the nicotine plasma concentration-time profiles in arterial and jugular venous blood after using a nicotine inhaler were compared with those achieved after cigarette smoking a in seven healthy habitual smokers.
RESULTS: After use of the inhaler, arterial nicotine concentrations rose slowly to a maximum level of 5. 9 +/- 1.5 ng/ml at a mean time to reach peak concentration (t(max)) of 9.0 +/- 1.1 min, whereas jugular venous nicotine levels peaked at 25.4 +/- 5.4 ng/ml at 6.7 +/- 0.3 min. The concentration-time curves indicate that the absorption occurs mainly via the mucosa of the oral cavity and the pharynx, and that there is minimal absorption via the lungs. In contrast, after smoking a cigarette, arterial nicotine plasma concentrations rose quickly to a maximum level of 49. 2 +/- 9.7 ng/ml after 4.0 +/- 0.6 min, while the maximum concentration of nicotine in the jugular vein was 22.4 +/- 3.9 ng/ml after 6.4 +/- 0.4 min, indicating primarily pulmonary absorption of nicotine.
CONCLUSION: Nicotine absorption after use of the vapour inhaler occurs primarily via the mucosa of the oral cavity; the absorption occurs slowly and the arterial nicotine concentration spike, typical of cigarette smoking, is avoided. Thus, the likelihood for abuse of the nicotine inhaler is probably small.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10663452     DOI: 10.1007/s002280050007

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

Review 1.  Recent findings in the pharmacology of inhaled nicotine: Preclinical and clinical in vivo studies.

Authors:  Asti Jackson; Ben Grobman; Suchitra Krishnan-Sarin
Journal:  Neuropharmacology       Date:  2020-06-24       Impact factor: 5.250

Review 2.  Biomarkers of exposure to new and emerging tobacco delivery products.

Authors:  Suzaynn F Schick; Benjamin C Blount; Peyton Jacob; Najat A Saliba; John T Bernert; Ahmad El Hellani; Peter Jatlow; R Steven Pappas; Lanqing Wang; Jonathan Foulds; Arunava Ghosh; Stephen S Hecht; John C Gomez; Jessica R Martin; Clementina Mesaros; Sanjay Srivastava; Gideon St Helen; Robert Tarran; Pawel K Lorkiewicz; Ian A Blair; Heather L Kimmel; Claire M Doerschuk; Neal L Benowitz; Aruni Bhatnagar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-18       Impact factor: 5.464

3.  Video-based kinetic analysis of calcification in live osteogenic human embryonic stem cell cultures reveals the developmentally toxic effect of Snus tobacco extract.

Authors:  Ivann K C Martinez; Nicole R L Sparks; Joseph V Madrid; Henry Affeldt; Madeline K M Vera; Bir Bhanu; Nicole I Zur Nieden
Journal:  Toxicol Appl Pharmacol       Date:  2018-11-20       Impact factor: 4.219

4.  Chronic intermittent nicotine delivery via lung alveolar region-targeted aerosol technology produces circadian pharmacokinetics in rats resembling human smokers.

Authors:  Xuesi M Shao; Siyu Liu; Eon S Lee; David Fung; Hua Pei; Jing Liang; Ross Mudgway; Jingxi Zhang; Jack L Feldman; Yifang Zhu; Stan Louie; Xinmin S Xie
Journal:  J Appl Physiol (1985)       Date:  2018-09-20

Review 5.  The reinforcement threshold for nicotine as a target for tobacco control.

Authors:  Mehmet Sofuoglu; Mark G LeSage
Journal:  Drug Alcohol Depend       Date:  2012-05-21       Impact factor: 4.492

6.  Developing a Rational Approach to Tobacco Use Treatment in Pulmonary Practice: A Review of the Biological Basis of Nicotine Addiction.

Authors:  Frank T Leone; Sarah Evers-Casey
Journal:  Clin Pulm Med       Date:  2012-03-01

7.  Nicotine delivery to rats via lung alveolar region-targeted aerosol technology produces blood pharmacokinetics resembling human smoking.

Authors:  Xuesi M Shao; Bin Xu; Jing Liang; Xinmin Simon Xie; Yifang Zhu; Jack L Feldman
Journal:  Nicotine Tob Res       Date:  2012-12-13       Impact factor: 4.244

Review 8.  Pharmacotherapy for tobacco cessation: nicotine agonists, antagonists, and partial agonists.

Authors:  Maher Karam-Hage; Paul M Cinciripini
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

Review 9.  The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments.

Authors:  N G Schneider; R E Olmstead; M A Franzon; E Lunell
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 10.  Nicotine chemistry, metabolism, kinetics and biomarkers.

Authors:  Neal L Benowitz; Janne Hukkanen; Peyton Jacob
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.